Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have received an average recommendation of "Hold" from the ten research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.33.

Several research firms recently weighed in on FULC. Cantor Fitzgerald downgraded Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Thursday, September 12th. Stifel Nicolaus cut Fulcrum Therapeutics from a "buy" rating to a "hold" rating and lowered their price objective for the company from $22.00 to $3.00 in a research report on Thursday, September 12th. Leerink Partnrs lowered shares of Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 12th. Bank of America cut shares of Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and decreased their target price for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th.

Fulcrum Therapeutics Trading Down 1.7 %

NASDAQ FULC traded down $0.07 during trading hours on Friday, hitting $3.96. 478,275 shares of the company's stock traded hands, compared to its average volume of 980,592. Fulcrum Therapeutics has a 52 week low of $2.86 and a 52 week high of $13.70. The firm has a market capitalization of $213.60 million, a P/E ratio of -12.77 and a beta of 2.14. The business's fifty day moving average price is $3.51 and its two-hundred day moving average price is $5.91.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. National Bank of Canada FI lifted its stake in shares of Fulcrum Therapeutics by 869.6% during the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company's stock worth $28,000 after acquiring an additional 4,000 shares during the last quarter. Profund Advisors LLC bought a new position in Fulcrum Therapeutics in the 2nd quarter valued at $68,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company's stock worth $43,000 after purchasing an additional 4,701 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Fulcrum Therapeutics during the second quarter valued at $82,000. Finally, Walleye Capital LLC purchased a new stake in shares of Fulcrum Therapeutics during the third quarter valued at $59,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.